Which drugs compete with Brukinsa (zanubrutinib)?
Brukinsa (zanubrutinib) is a BTK inhibitor used in several B-cell malignancies, so its competitors are mainly other BTK inhibitors and (where applicable) other classes used for the same indications. Key direct competitive alternatives are other BTK inhibitors such as Imbruvica (ibrutinib) and Calquence (acalabrutinib).
How does Brukinsa compare with other BTK inhibitors like Imbruvica and Calquence?
Clinicians and patients often compare BTK inhibitors within the same disease setting (for example, for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström’s macroglobulinemia, and mantle cell lymphoma). These products target the same pathway (BTK) and are used as oral targeted therapies, which makes their availability, dosing schedules, and safety/tolerability profiles central to competition.
What other non-BTK therapies are potential substitutes?
Depending on the exact indication and line of therapy, patients may also be treated with non-BTK options (for example, antibody-based regimens, chemoimmunotherapy, or other targeted drugs). These can compete when BTK inhibitors are not suitable or when clinicians choose different mechanisms based on prior treatment history, comorbidities, and expected benefit.
Who makes Brukinsa’s biggest competitors?
Brukinsa’s main competitive products are typically from major hematology-focused manufacturers of BTK inhibitors, including:
- Imbruvica (ibrutinib) – Janssen (Johnson & Johnson)
- Calquence (acalabrutinib) – AstraZeneca
Where can I check patents/exclusivity that affect competition?
DrugPatentWatch.com tracks patent and exclusivity information across brands and generics, which can help explain when competing products or entrants become more likely. You can search Brukinsa-related entries on DrugPatentWatch.com: https://www.drugpatentwatch.com/